Compounds > mdl 27695
Page last updated: 2024-11-06

mdl 27695

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

MDL 27695: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72453
CHEMBL ID40258
SCHEMBL ID7015048
MeSH IDM0162620

Synonyms (10)

Synonym
1,7-heptanediamine, n,n'-bis(3-((phenylmethyl)amino)propyl)-
n,n'-bis[3-(benzylamino)propyl]heptane-1,7-diamine
n,n'-bis(3-((phenylmethyl)amino)propyl)-1,7-diaminoheptane
117654-71-4
mdl-27695
mdl 27695
CHEMBL40258
SCHEMBL7015048
DTXSID50151859
n,n'-bis{3-[(phenylmethyl)amino]propyl}-1,7-diaminoheptane

Research Excerpts

Effects

ExcerptReferenceRelevance
"MDL 27695 has also been shown to possess significant antimalarial effects both in vitro and in vivo, and it is possible that the marked suppression of polyamine biosynthesis described herein may contribute to its anti-malarial effects as well as its antiproliferative effects in mammalian cells."( Regulation of polyamine biosynthesis in rat hepatoma (HTC) cells by a bisbenzyl polyamine analogue.
Bitonti, AJ; Bush, TL; McCann, PP, 1989)		1

Compound-Compound Interactions

ExcerptReferenceRelevance
" three times per day for 3 days in combination with 2% alpha-difluoromethylornithine (DFMO; eflornithine) in drinking water effected cures of 47/54 mice infected with Plasmodium berghei."( Bis(benzyl)polyamine analogs inhibit the growth of chloroquine-resistant human malaria parasites (Plasmodium falciparum) in vitro and in combination with alpha-difluoromethylornithine cure murine malaria.
Bitonti, AJ; Bush, TL; Dumont, JA; Edwards, ML; McCann, PP; Sjoerdsma, A; Stemerick, DM, 1989)		0.28

Dosage Studied

ExcerptRelevanceReference
" donovani infections in BALB/c mice were suppressed greater than 99% after intraperitoneal dosing for 20 days with a total dose of 150 mg of MDL 27,695 per kg of body weight or 560 mg of Sbv per kg."( Suppression of Leishmania donovani by oral administration of a bis(benzyl)polyamine analog.
Baumann, RJ; Bitonti, AJ; McCann, PP, 1991)		0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID215498In vitro growth Inhibitory activity against LAB 110 Strain of Trypanosoma brucei2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID215363In vitro growth Inhibitory activity against K269 Strain of Trypanosoma brucei. 2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID81368Anti-proliferative activity against HeLa cells2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID87901Ability to cause aggregation of purified HeLa cell DNA1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID215500In vitro growth inhibitory activity against Trypanosoma brucei strain K243 (As-10-3)2001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Novel alkylpolyamine analogues that possess both antitrypanosomal and antimicrosporidial activity.
AID421189Antiparasitic activity against Plasmodium falciparum2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Recent advances in the development of polyamine analogues as antitumor agents.
AID556064Activity of Encephalitozoon cuniculi polyamine oxidase assessed as hydrogen peroxide release per mg protein by spectrophotometry2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Metabolism of an alkyl polyamine analog by a polyamine oxidase from the microsporidian Encephalitozoon cuniculi.
AID86842Ability to inhibit 50% growth of HeLa cells1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID54444Ability to displace ethidium bromide from calf thymus DNA1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID162553Ability to displace ethidium bromide from double stranded synthetic poly (dG-dC)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID215502In vitro growth inhibitory activity against Trypanosoma brucei strain LAB1102001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Novel alkylpolyamine analogues that possess both antitrypanosomal and antimicrosporidial activity.
AID80472Antitumor activity was determined against H157 cell line2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID215499In vitro growth inhibitory activity against Trypanosoma brucei strain K2432001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Novel alkylpolyamine analogues that possess both antitrypanosomal and antimicrosporidial activity.
AID215362In vitro growth Inhibitory activity against K243 Strain of Trypanosoma brucei. 2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID80492In vitro activity against H157 non-small-cell lung tumor line (non-SCLC) cultures.2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID221123Antimalarial activity was determined against Leishmania donovani in hamsters2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID215501In vitro growth inhibitory activity against Trypanosoma brucei strain K2692001Bioorganic & medicinal chemistry letters, Jun-18, Volume: 11, Issue:12
Novel alkylpolyamine analogues that possess both antitrypanosomal and antimicrosporidial activity.
AID86980Compound was evaluated for its ability to inhibit proliferation of HeLa cells2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID556065Activity of Encephalitozoon cuniculi polyamine oxidase assessed as hydrogen peroxide release per mg protein by spectrophotometry relative to 0.1 mM N'-acetylspermine2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Metabolism of an alkyl polyamine analog by a polyamine oxidase from the microsporidian Encephalitozoon cuniculi.
AID162413Ability to displace ethidium bromide from double stranded synthetic Poly (dA-dT)1991Journal of medicinal chemistry, Aug, Volume: 34, Issue:8
Synthesis and DNA-binding properties of polyamine analogues.
AID129292Antimalarial activity was determined against Leishmania donovani in mice (Mus musculus)2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID215361In vitro growth Inhibitory activity against K243 As-10-3 Strain of Trypanosoma brucei2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID78586In vitro activity against H82 small-cell lung tumor line (SCLC) cultures.2001Journal of medicinal chemistry, Jan-04, Volume: 44, Issue:1
Terminally alkylated polyamine analogues as chemotherapeutic agents.
AID556066Activity of Encephalitozoon cuniculi polyamine oxidase assessed as hydrogen peroxide release per mg protein by spectrophotometry relative to 1 mM N'-acetylspermine2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Metabolism of an alkyl polyamine analog by a polyamine oxidase from the microsporidian Encephalitozoon cuniculi.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (18.75)18.7374
1990's8 (50.00)18.2507
2000's5 (31.25)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.72 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.61 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (11.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (88.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzaldehyde
[no description available]		1.9710benzaldehydesEC 3.1.1.3 (triacylglycerol lipase) inhibitor;
EC 3.5.5.1 (nitrilase) inhibitor;
flavouring agent;
fragrance;
odorant receptor agonist;
plant metabolite
n'-acetylspermine
N(1)-acetylspermine : An acetylspermine carrying an acetyl group at position N(1).		2.0510acetamides;
acetylspermine		human metabolite
putrescine
[no description available]		2.3820alkane-alpha,omega-diamineantioxidant;
fundamental metabolite
spermidine
[no description available]		2.3820polyazaalkane;
triamine		autophagy inducer;
fundamental metabolite;
geroprotector
spermine
[no description available]		2.6730polyazaalkane;
tetramine		antioxidant;
fundamental metabolite;
immunosuppressive agent
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		1.9710aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
eflornithine
Eflornithine: An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway.. eflornithine : A fluoroamino acid that is ornithine substituted by a difluoromethyl group at position 2.		2.6730alpha-amino acid;
fluoroamino acid		trypanocidal drug
hexamethylene bisacetamide
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208		1.9810acetamides
entinostat
[no description available]		3.1410benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
n(1),n(11)-diethylnorspermine
N(1),N(11)-diethylnorspermine: structure given in first source		4.3230
n(1), n(12)-diethylspermine
N(1), N(12)-diethylspermine: structure in first source. N(1),N(12)-diethylspermine : A substituted spermine that is spermine in which a hydrogen attached to each of the primary amino groups has been replaced by an ethyl group.		4.0420polyazaalkane;
secondary amino compound;
substituted spermine;
tetramine		antineoplastic agent
vorinostat
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).		3.1410dicarboxylic acid diamide;
hydroxamic acid		antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor
dipropylenetriame
N-(3-aminopropyl)-1,3-propanediamine: structure in first source		1.9710polyazaalkanealgal metabolite;
plant metabolite
melarsen oxide
melarsen oxide: inhibits glutathione reductase		3.110
n(1),n(14)-bis(ethyl)homospermine
N(1),N(14)-bis(ethyl)homospermine: structure given in first source; depletes polyamines and inhibits the growth of tumor cells in tissue culture		4.0420
s-adenosyl-3-thio-1,8-diaminooctane
S-adenosyl-3-thio-1,8-diaminooctane: structure given in first source		3.110
n(1),n(8)-diethylspermidine
N(1),N(8)-diethylspermidine: regulator of ornithine decarboxylase		3.110
be 4-4-4-4
BE 4-4-4-4: structure given in first source		3.1410
trichostatin a
trichostatin A: chelates zinc ion in the active site of histone deacetylases, resulting in preventing histone unpacking so DNA is less available for transcription; do not confuse with TRICHOSANTHIN which is a protein; found in STREPTOMYCES		3.1410antibiotic antifungal agent;
hydroxamic acid;
trichostatin		bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector
s-adenosyl-1,12-diamino-3-thio-9-azadodecane
S-adenosyl-1,12-diamino-3-thio-9-azadodecane: structure given in first source		3.110
mitoguazone
Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.		3.110guanidines;
hydrazone		antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
antimony
Antimony: A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.		1.9710metalloid atom;
pnictogen
cgc 11047
CGC 11047: may prove useful in promoting regression of choroidal neovascularization		3.1410
antimony sodium gluconate
Antimony Sodium Gluconate: Antimony complex where the metal may exist in either the pentavalent or trivalent states. The pentavalent gluconate is used in leishmaniasis. The trivalent gluconate is most frequently used in schistosomiasis.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Opportunistic Infections
An infection caused by an organism which becomes pathogenic under certain conditions, e.g., during immunosuppression.		02.9210
Breast Cancer
[description not available]		02.9610
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.9610
Black Fever
[description not available]		02.6730
Leishmaniasis, Visceral
A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.		02.6730
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		0210
P carinii Pneumonia
[description not available]		0210
AIDS-Related Opportunistic Infections
Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.		0210
Pneumonia, Pneumocystis
A pulmonary disease in humans occurring in immunodeficient or malnourished patients or infants, characterized by DYSPNEA, tachypnea, and HYPOXEMIA. Pneumocystis pneumonia is a frequently seen opportunistic infection in AIDS. It is caused by the fungus PNEUMOCYSTIS JIROVECII. The disease is also found in other MAMMALS where it is caused by related species of Pneumocystis.		0210
Infections, Plasmodium
[description not available]		02.3820
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.3820
Experimental Hepatoma
[description not available]		01.9710